Generic placeholder image

Current Drug Targets - Infectious Disorders


ISSN (Print): 1568-0053
ISSN (Online): 1875-5852

The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs)

Author(s): Ronald B. Moss, Fred C. Jensen, Dennis J. Carlo and Mark. R. Wallace

Volume 1, Issue 1, 2001

Page: [11 - 17] Pages: 7

DOI: 10.2174/1568005013343236


Structured treatment interruptions (STIs) have evolved as an experimental approach of interrupting highly active antiretroviral therapy (HAART) similar to cycles of cancer chemotherapy in order to develop immune control of HIV-1. There are multiple, on-going clinical trials examining interruptions in antiviral therapy with and without immune-based therapies. If successful in developing immune control, STIs may be clinically useful but require large scale clinical trials to prove their utility and safety.

Keywords: Structured Treatment Interruptions STIs, antiretroviral therapy HAART

© 2024 Bentham Science Publishers | Privacy Policy